PVLA
Palvella Therapeutics, Inc.
1W: +5.4%
1M: -0.0%
3M: +10.4%
YTD: +20.1%
1Y: +332.0%
$120.39
+4.16 (+3.58%)
After Hours: $119.00 (-1.39, -1.15%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$25.3M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.4B
52W Range18.225-151.18
Volume259,922
Avg Volume307,145
Beta-0.29
Dividend—
Analyst Ratings
Company Info
CEOWesley H. Kaupinen
Employees14
SectorHealthcare
IndustryBiotechnology
IPO Date2015-01-02
Websitepalvellatx.com
125 Strafford Avenue
Wayne, PA 19087
US
Wayne, PA 19087
US
484 253 1461
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
Latest News
Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal
Director Buys $500,000 Worth of Palvella Therapeutics Shares After Phase 3 Win
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
Kathleen Goin Sells 4,302 Shares of Palvella Therapeutics (NASDAQ:PVLA) Stock
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Goin Kathleen | M-Exempt | 2,154 | $7.14 | 2026-03-18 |
| Goin Kathleen | M-Exempt | 2,148 | $9.08 | 2026-03-18 |
| Goin Kathleen | S-Sale | 2,268 | $117.56 | 2026-03-18 |
| Goin Kathleen | S-Sale | 1,730 | $118.37 | 2026-03-18 |
| Goin Kathleen | S-Sale | 304 | $119.08 | 2026-03-18 |